Skip to main content

Sartorius AG (SRT.DE)

Frankfurt Stock Exchange (XETRA) Healthcare Medical - Instruments & SuppliesView data quality →
43.1Fair

ValueMarkers Composite Index

Top 11%#39,702 of 44,707
Overvalued

196% above intrinsic value ($67)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-3.04
Low Risk
Altman
2.11
Grey Zone
DCF Value
$67
Overvalued
ROIC
4.5%
Low
P/E
96.5
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Sartorius AG (SRT.DE) — VMCI valuation read

Sartorius AG sits at VMCI 43/100, with the Healthcare sector median at 50. That 7-point spread is the first thing to note on SRT.DE: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on SRT.DE are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on SRT.DE: SRT.DE trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of -1.2x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

SRT.DE fell 0.8% over the trailing 7 days, with a -20.6% read on a 30-day basis.

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

CEO: Michael Grosse13,573 employeesDEwww.sartorius.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in SRT.DE’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.